AUS
NZ
UK
CA
USA
IND
Noxopharm Limited (ASX:NOX), an Australian clinical-stage drug developer, reported major advancements in its Sofra™ technology platform during the June 2026 quarter. The company revealed enhanced cancer-fighting capabilities and expanded collaborations, highlighting the adaptability of its oligonucleotide platform. Global biopharma leader CSL will present Noxopharm’s assets at an international conference in late August, while peer-reviewed validation in Nature Reviews Rheumatology strengthens the scientific foundation of Noxopharm’s breakthrough discovery. With SOF-SKN™ manufacturing underway and upcoming pre-IND discussions with the US FDA, investors are closely monitoring progress toward clinical trials targeting autoimmune diseases and cancer indications.
Key Points
- Noxopharm Limited (ASX:NOX) is advancing therapies via its Sofra™ platform targeting cancer, autoimmune, and inflammatory diseases.
- New data demonstrate Sofra technology’s ability to activate Toll-like receptor 8 (TLR8), boosting the efficacy of chemotherapy and radiotherapy.
- CSL will present Noxopharm’s oligonucleotide applications in self-amplifying mRNA vaccines at the Options for the Control of Influenza XIII Conference in August 2026, Washington DC.
- Manufacturing of SOF-SKN™ has started, supported by new dosing regimen data and preparations for a pre-IND FDA meeting with a global clinical research organisation.
- InhaTarget Therapeutics’ studies using Noxopharm’s oligonucleotides showed over 75% reduction in lung inflammation in animal models, validating therapeutic potential beyond oncology.
- Noxopharm’s discovery received peer-reviewed recognition in Nature Reviews Rheumatology, affirming the scientific rigor of its platform.
- Investors should watch for FDA pre-IND meeting outcomes and clinical trial progress in cutaneous lupus erythematosus and other autoimmune and cancer indications.
Noxopharm Extends Sofra™ Platform to Cancer Immunotherapy via TLR8 Activation
During the June quarter, Noxopharm announced successful extension of its Sofra™ platform into cancer immunotherapy by developing oligonucleotides that significantly amplify Toll-like receptor 8 (TLR8) activity beyond current clinical candidates. This enhancement is poised to improve the effectiveness of standard cancer treatments such as chemotherapy and radiotherapy, potentially marking a breakthrough in immuno-oncology.
The timing coincides with robust market growth projections, with the immuno-oncology sector expected to expand from US$35 billion in 2025 to US$185 billion by 2035. Noxopharm’s immune system-based technology positions it strongly within this high-growth field. The platform’s demonstrated versatility across cancer and autoimmune diseases underscores its broad scientific and commercial potential pending successful clinical development.
CSL to Showcase Noxopharm’s mRNA Vaccine Technology at Washington DC Conference
CSL, a global biopharmaceutical leader, will present Noxopharm’s Sofra-derived oligonucleotides at the Options for the Control of Influenza XIII Conference in late August 2026 in Washington DC. The presentation will highlight applications in enhancing self-amplifying mRNA vaccines, validating Noxopharm’s technology and expanding its potential beyond internal pipelines.
This endorsement from CSL signals strong industry interest and positions Noxopharm’s assets as valuable intellectual property in vaccine development. The collaboration diversifies Noxopharm’s revenue streams beyond cancer and autoimmune programs, reducing concentration risk and enhancing commercial prospects.
InhaTarget Therapeutics Validates Sofra™ Platform in Lung Inflammation Studies
Belgium-based InhaTarget Therapeutics reported positive preclinical results using Noxopharm’s oligonucleotides in inhaled therapies targeting lung inflammation. Following Material Transfer Agreements in October 2024 and May 2025, InhaTarget demonstrated over 75% reduction in lung inflammation in animal models with optimised lipid nanoparticle formulations.
This success validates the Sofra platform’s applicability in respiratory medicine and its adaptability to inhalation delivery. With the global inhaled therapies market valued at US$11.6 billion in 2024 and projected to exceed US$16 billion by 2034, these findings highlight significant commercial opportunity and accelerate external validation without requiring Noxopharm to internally fund all research.
Peer-Reviewed Recognition in Nature Reviews Rheumatology Enhances Scientific Credibility
Noxopharm’s foundational science received prestigious peer-reviewed validation through inclusion in a global research overview on TLR7’s role in systemic lupus, published in Nature Reviews Rheumatology. The collaborative work with Hudson Institute of Medical Research and international researchers affirms the scientific rigor of the Sofra platform’s breakthrough discovery.
This high-profile recognition bolsters credibility with partners, regulators, and investors, documenting the biological plausibility and mechanism of action essential for regulatory approvals and future pipeline development.
SOF-SKN™ Manufacturing Initiated and Preclinical Characterisation Underway
Manufacturing of SOF-SKN™ commenced during the quarter, marking a vital shift from research to development. The process includes rigorous physical, chemical, and biological quality controls to ensure manufacturing efficiency and supply chain stability. Produced batches will support preclinical dose range-finding, therapeutic modeling, and stability profiling, which to date show favorable characteristics.
This milestone reflects Noxopharm’s readiness to advance SOF-SKN toward clinical trials, aligning with regulatory standards and reducing timelines for human studies.
New SOF-SKN™ Dosing Data Strengthens Regulatory Submission
Promising dosing regimen data for SOF-SKN™ published during the quarter confirmed key drug characteristics, enhancing the regulatory submission package. Optimising dosing is critical for balancing efficacy and safety, and these findings reduce uncertainty regarding clinical behaviour.
The data supports upcoming pre-IND discussions with the US FDA, demonstrating thorough preclinical evaluation and a disciplined clinical development plan that reassures investors of methodical advancement toward human trials.
FDA Pre-IND Meeting Preparation Supported by Global CRO
Noxopharm engaged a leading global clinical research organisation to prepare for a pre-IND meeting with the US FDA, a crucial regulatory step to discuss clinical trial design and requirements for SOF-SKN™. This strategic collaboration ensures compliance with FDA expectations and optimises the IND application process.
Such professional regulatory support exemplifies mature execution and positions the company for accelerated clinical trial initiation, particularly for cutaneous lupus erythematosus and other indications.
SOF-SKN™ Targeting Cutaneous Lupus with Expansion to Broader Autoimmune Diseases
SOF-SKN™ is initially being developed for cutaneous lupus erythematosus (CLE), a skin-specific autoimmune condition with a global market exceeding US$3.3 billion. Following CLE, Noxopharm plans to expand development into psoriasis, dermatomyositis, rheumatoid arthritis, diabetes, and other immune-related diseases, reflecting a multi-indication strategy.
This phased approach focuses on establishing proof-of-concept in a defined population before pursuing larger autoimmune markets, which affect millions worldwide and are growing steadily, supporting long-term commercial potential.
Strategic Partnerships and Market Validation Fuel Commercialisation Momentum
In the June quarter, Noxopharm strengthened external partnerships and achieved third-party validation for its Sofra platform across multiple therapeutic areas. Licensing to established partners like CSL and InhaTarget, alongside internal development of SOF-SKN™, creates diversified value drivers and mitigates development risks.
CEO Dr Olivier Laczka highlighted, "The progress developing the Sofra platform and extending it into cancer treatment demonstrates the technology’s versatility, further evidenced by our global partnerships."
This commercialisation strategy leverages external validation and revenue generation, attracting international collaborators and investors, and enhancing the platform’s long-term commercial viability.
